DekaBank Deutsche Girozentrale Purchases 57,088 Shares of Eli Lilly And Co (NYSE:LLY)

Share on StockTwits

DekaBank Deutsche Girozentrale lifted its position in Eli Lilly And Co (NYSE:LLY) by 6.4% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 947,315 shares of the company’s stock after acquiring an additional 57,088 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Eli Lilly And Co were worth $105,838,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Comerica Securities Inc. raised its stake in Eli Lilly And Co by 80.6% during the 4th quarter. Comerica Securities Inc. now owns 4,154 shares of the company’s stock valued at $481,000 after purchasing an additional 1,854 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Eli Lilly And Co by 0.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,070,587 shares of the company’s stock valued at $239,597,000 after purchasing an additional 18,958 shares during the last quarter. First Citizens Bank & Trust Co. raised its stake in Eli Lilly And Co by 21.6% during the 1st quarter. First Citizens Bank & Trust Co. now owns 12,878 shares of the company’s stock valued at $1,671,000 after purchasing an additional 2,284 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in Eli Lilly And Co during the 1st quarter valued at $3,900,000. Finally, Lodestar Investment Counsel LLC IL raised its stake in Eli Lilly And Co by 5.0% during the 1st quarter. Lodestar Investment Counsel LLC IL now owns 10,870 shares of the company’s stock valued at $1,410,000 after purchasing an additional 520 shares during the last quarter. 79.48% of the stock is owned by institutional investors and hedge funds.

Shares of LLY stock opened at $115.70 on Wednesday. Eli Lilly And Co has a 52-week low of $101.27 and a 52-week high of $132.13. The firm has a market cap of $109.84 billion, a PE ratio of 20.85, a price-to-earnings-growth ratio of 2.01 and a beta of 0.19. The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 4.98. The firm has a fifty day simple moving average of $110.74.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 30th. The company reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.45 by $0.05. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 70.86%. The company had revenue of $5.64 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the prior year, the company posted $1.48 EPS. The business’s revenue was up .9% on a year-over-year basis. On average, research analysts forecast that Eli Lilly And Co will post 5.72 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a $0.645 dividend. This represents a $2.58 annualized dividend and a dividend yield of 2.23%. The ex-dividend date of this dividend is Wednesday, August 14th. Eli Lilly And Co’s payout ratio is 46.49%.

In other news, VP Michael J. Harrington sold 16,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $116.72, for a total value of $1,867,520.00. Following the sale, the vice president now owns 110,300 shares of the company’s stock, valued at approximately $12,874,216. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Joshua L. Smiley bought 426 shares of the stock in a transaction dated Wednesday, June 5th. The stock was purchased at an average cost of $118.03 per share, for a total transaction of $50,280.78. Following the acquisition, the chief financial officer now owns 30,410 shares in the company, valued at approximately $3,589,292.30. The disclosure for this purchase can be found here. 0.11% of the stock is currently owned by corporate insiders.

LLY has been the subject of several research analyst reports. BMO Capital Markets upped their target price on shares of Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. Goldman Sachs Group initiated coverage on shares of Eli Lilly And Co in a research note on Tuesday, May 28th. They set a “buy” rating and a $135.00 target price for the company. Edward Jones upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 target price for the company in a research note on Tuesday, April 23rd. Cantor Fitzgerald restated a “buy” rating and issued a $143.00 price objective on shares of Eli Lilly And Co in a research note on Tuesday, April 30th. Finally, ValuEngine cut shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Friday, June 28th. Nine equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $123.49.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Profit Margin

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Icahn Enterprises  Downgraded by BidaskClub
Icahn Enterprises Downgraded by BidaskClub
Intercept Pharmaceuticals  Lifted to Hold at BidaskClub
Intercept Pharmaceuticals Lifted to Hold at BidaskClub
Independent Bank Co.  Upgraded at BidaskClub
Independent Bank Co. Upgraded at BidaskClub
Hub Group  Lifted to “Hold” at BidaskClub
Hub Group Lifted to “Hold” at BidaskClub
Heritage Commerce  Upgraded at BidaskClub
Heritage Commerce Upgraded at BidaskClub
Hemisphere Media Group  Upgraded at BidaskClub
Hemisphere Media Group Upgraded at BidaskClub


© 2006-2019 Ticker Report